An investigation on behalf of investors in shares of United Therapeutics Corporation (NASDAQ:UTHR) was announced over potential breaches of fiduciary duties by certain officers and directors at United Therapeutics.

The investigation by a law firm concerns whether certain United Therapeutics Corporation officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Silver Springs, MD based United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. United Therapeutics Corporation reported that its annual Total Revenue rose from over $1.59 billion in 2016 to over $1.72 billion in 2017 and that its Net Income declined from $713.70 million in 2016 to $488.90 million in 2017.

On February 21, 2018, United Therapeutics Corporation disclosed that its cost of product sales was above expectations due to an increase in the royalty rate United Therapeutics is required to pay Eli Lilly for Adcirca under an amended licensed agreement.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) declined from $139.22 per share on February 16, 2018 to as low as $115.12 per share on February 22, 2018.